LymphomaArchives
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Lymphoma 1 min.
Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard-of-care therapy with frontline DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, rituximab). However, treatment strategies following relapse after DA-EPOCH-R...
CD47: a promising target for immunotherapy in relapsed/refractory malignant lymphoma
Lymphoma 1 min.
CD47 is an immune checkpoint molecule widely expressed on various cell types and has emerged as a key target in cancer immunotherapy due to its role in mediating tumor immune escape viathe ‘don't eat me' signal. In lymphoma, CD47 expression shows heterogeneity across subtypes, with elevated...
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma
Lymphoma 1 min.
We conducted a retrospective, multi-center, real-world study to evaluate efficacy and safety of zanubrutinib combination therapy as first-line treatment for diffuse large B-cell lymphoma (DLBCL) between August 2020 and August 2025. Patients received RCHOP as standard therapy, while those with central...
Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma
Lymphoma 1 min.
Macrophages are attractive targets for novel cancer immunotherapy approaches since they can infiltrate into the tumor microenvironment and have the capacity to engulf and destroy cancer cells by phagocytosis. The CD47/SIRPα axis is a key immune checkpoint that regulates macrophages' ability to...
